lunedì, 5 giugno 2023
5 Settembre 2017

FDA Grants LN-144 Fast Track Status for Melanoma

September 1, 2017 – The FDA has granted LN-144, an adoptive cell therapy that uses tumor-infiltrating lymphocyte (TIL) technology developed by Iovance Biotherapeutics, a fast track designation for the treatment of patients with advanced melanoma. The designation is based on data Iovance submitted from C-144-01, a phase II multicenter study. Efficacy data for 14 of the 16 patients who were treated showed that LN-144 induced an overall response rate … (leggi tutto)